VA
RGNX icon

Vident Advisory’s Regenxbio RGNX Stock Holding History

Vident Advisory’s Portfolio RGNX Stock Details RGNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-12,918
Closed -$151K – 1529
2024
Q2 		$151K Buy
12,918
+3,386
+36% +$52.7K ﹤0.01% 1324
2024
Q1 		$201K Sell
9,532
-511
-5% -$9.09K ﹤0.01% 1217
2023
Q4 		$180K Sell
10,043
-139
-1% -$2.45K ﹤0.01% 1236
2023
Q3 		$168K Buy
+10,182
New +$185K 0.01% 1151

Other funds holding RGNX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
IHAM
Integral Health Asset Management New York $2.09B AUM 112.84% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

Vident Advisory's RGNX Position: Q3 2024 in Review

Vident Advisory sold out of Regenxbio (RGNX) in Q3 2024, closing a stake of 12,918 shares — an estimated $151K sold.

Vident Advisory first reported a position in RGNX in Q3 2023 and held it in 4 quarters. The position peaked at $201K in Q1 2024. 186 funds tracked by Wall St. Rank hold RGNX as of Q3 2024.

  • Vident Advisory reported no remaining Regenxbio position as of Q3 2024 after selling out during the quarter.
  • Vident Advisory sold 12,918 Regenxbio shares in Q3 2024, an estimated $151K.
  • Vident Advisory first reported a position in Regenxbio in Q3 2023 and held it in 4 quarters.
  • Vident Advisory's Regenxbio position peaked at $201K in Q1 2024.
  • 186 funds tracked by Wall St. Rank held Regenxbio as of Q3 2024.

Based on Vident Advisory's 13F filing for Q3 2024, filed 14 Nov 2024.